Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions

Wimolsiri Iamsumang1, Kumutnart Chanprapaph1, Chonlaphat Sukasem2

  • 1Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Dermatology (Basel, Switzerland)
|October 4, 2023
PubMed
Abstract

Insights

Co-trimoxazole can cause various skin reactions, with male gender, HIV, and prolonged use increasing severe risks. Specific human leukocyte antigen (HLA) types are linked to different reaction subtypes, aiding in predicting severe cutaneous adverse drug reactions (SCARs).

Area of Science:

  • Pharmacogenomics
  • Dermatology
  • Immunology

Background:

  • Co-trimoxazole is a frequent cause of cutaneous adverse drug reactions (CADRs).
  • Limited data exists on the genotypic and phenotypic characteristics of these reactions.
  • Understanding these factors is crucial for predicting and managing severe cases.

Purpose of the Study:

  • To investigate clinical features, genetic predispositions, laboratory findings, and treatment outcomes in co-trimoxazole-induced CADRs.
  • To identify variables associated with severe cutaneous adverse reactions (SCARs).
  • To explore the link between human leukocyte antigen (HLA) types and specific CADR phenotypes.

Main Methods:

  • Retrospective review of medical records for co-trimoxazole-induced CADR cases (October 2015 - October 2021).
  • Evaluation of clinical characteristics and laboratory investigations.
  • Emphasis on human leukocyte antigen (HLA) class I and HLA-DRB1 genotyping in relation to reaction subtypes.

Main Results:

  • Seventy-two patients were included; 72% were female, with a mean age of 38.0 years.
  • Common reactions included maculopapular eruption (56.9%), DRESS (23.6%), and Stevens-Johnson syndrome (12.5%).
  • Male gender, HIV infection, prophylactic, and prolonged co-trimoxazole use were associated with SCARs. Specific HLA alleles (e.g., HLA-B*38:02, HLA-A*11:01) were linked to SJS, DRESS, and MPE.

Conclusions:

  • Co-trimoxazole can induce diverse CADR phenotypes.
  • Predictors for co-trimoxazole-induced SCARs include male gender, HIV, prophylactic/prolonged use, and specific HLA alleles.
  • Genotypic and phenotypic analysis offers insights into predicting severe drug reactions.

Related Concept Videos

Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
3.9K
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
871
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
178
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.0K
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
215
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.9K